Depth in products and pharma partnerships Marc Voigt, CEO - The global leader in developing LAG-3 therapeutics - Bell Potter
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Depth in products and pharma partnerships
Marc Voigt, CEO
The global leader in developing LAG - 3 therapeuticsNotice: Forward Looking Statements The purpose of the presentation is to provide an updat e of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction wi th past and future announcements made by Immutep and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company’s filings to the ASX and SEC for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the informatio n. Any forward - looking statements in this presentation have been prepared based on a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immutep’s control. Important factors that could cause actual results to differ materia lly from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Immutep’s current intentions, plans, expectations and beliefs about t he future, you are urged to view all forward - looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by Immutep. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.
LAG- 3 Pioneer:
French immunologist
Prof Frédéric Triebel ,
Immutep CMO & CSO
LAG- 3 is the most
promising new
immune checkpointExposure to two very large and
growing pharmaceutical markets
Oncology 2
Autoimmune 1
US$149.40 US$176.50
billion billion
growing at growing at
4.3% CAGR 7.6% CAGR
1 https://www.prnewswire.com/news-releases/oncologycancer-drugs-market-to-reach-176-50-bn-globally-by-2025-at-7-6-cagr-allied-market-research-300937810.html
2https://www.prnewswire.com/news-releases/the-global-autoimmune-disease-therapeutics-market-size-is-expected-to-reach-149-4-billion-by-2025--rising-at-a-market-growth-of-4-34-cagr-during-the-forecast-period-
300902336.htmlMultiple LAG - 3 products
LAG525 (IMP701)
Five clinical trials ongoing in
multiple cancer indications for
more than 1,000 patients
GSK’781 (IMP731) EFTI
Three trials with more than 340 Six trials in multiple cancers,
patients, including ongoing plus COVID- 19 study, in total
Phase II clinical study in 242 involving more than 550
ulcerative colitis patients patients
IMP761
Advancing well through preclinical
steps for autoimmune diseases
Multiple pharma partnerships, already income generatingApproximately 70 - 80% of
patients do not respond to
an immune check point
therapy, called anti - PD- 1 Activating antigen
monotherapy. 1 presenting cells with
LAG- 3 via MHC II.
How do we improve the
immune response?
1 See for example Callahan at al Front. Oncol. (2015) 4:385 and Gauci at al Clin Cancer Res. (2019) Feb 1;25(3):946-956.Encouraging results for efti ,
building intrinsic value
• 6- month landmark showed improvement compared to placebo group
AIPAC Breast
• 48.3% Overall Response Rate compared to 38.4% in placebo group
Cancer
• Favourable results in different predefined patient subgroups
TACTI- Lung • Overall Response Rates are very favourable
002 Cancer & • 5 patients with complete disappearance of all lesions
Head • Encouraging efficacy for low PD - L1 expressing patients
and Neck who do not typically respond to PD - L1 therapy
INSIGHT- Solid • 4 1.7% of pa t ie n t s s h owe d a Pa rt ia l Re s p on s e
004 Cancers • Ea rly a nt i- t u m ou r a c t ivit y s ig n a ls in d iffic u lt t o t re a t c a n c e rs
TACTI-
• Deep durable responses
mel • 50% of patients decrease of ≥ 75% in the target lesions
Melanoma
• 38 % of pa t ie nt s t re a t e d for ≥ 12 m on t h s
Efti’s safety profile enables it to be used in various combination settingsCollaboration with EOC Pharma “ Immutep’s recent AIPAC clinical trial results gave us a good indication of efti’s efficacy in metastatic breast cancer. Based on our analysis of the overall and subgroup data they reported, we have felt confident continuing our program in China.” Xiaoming Zou, CEO of EOC Pharma
2020 & 2021 News Flow*
• AIPAC - interim Overall Survival data to
be presented at San Antonio Breast
Cancer Symposium 2020: Dec 2020
• Other updates
20 20
Notes:
*The actual timing of future data readouts may differ from expected timing shown above. These dates are provided
on a calendar year basis.• Final data from TACTI - 002 2 nd line
HNSCC, more mature data from 2 nd
line NSCLC and expanded 1 st line
NSCLC cohorts
• Final data from INSIGHT - 004
• Ongoing regulatory engagement
• Updates from IMP761 20 21
• Progress from partnered programs
• Final data from AIPACSummary
4 LAG- 3 product 5 big pharma
candidates partnerships
Multiple active clinical Approx. 2,000 patients
trials across the globe
Corporate Snapshot
Ticker Symbols Securities on issue (1) Market Cap
(as at 20 November 2020) (as at 20 November 2020)
IMM (ASX)
492.9 m A$128.1m
IMMP (NASDAQ) ordinary shares
(1) Currently ~24% of the ordinary shares are represented by ADSs listed on NASDAQ where 1 ADS represents 10 ordinary shares. Please refer to la tes t Appendi x 2A released on ASX for a detailed
summary of all securities on issue. The above figure does not include a further 123.2m new ordinary shares which are expected to be issued on 25 November 2020 as part of the A$29.6m
capital raising announced on 19 November 2020. Total ordinary shares on issue post placement will be 616.1m.Th a n k you
You can also read
